<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174289</url>
  </required_header>
  <id_info>
    <org_study_id>2013PS003H</org_study_id>
    <secondary_id>ISROTH20092</secondary_id>
    <nct_id>NCT02174289</nct_id>
  </id_info>
  <brief_title>LV Endocardial Cardiac Resynchronisation Therapy</brief_title>
  <acronym>ENDO-CRT</acronym>
  <official_title>A Randomised Double-blinded Cross Over Study to Evaluate the Improvement of Left Ventricular Systolic Failure Using Targeted Left Ventricular Endocardial Lead Placement in Cardiac Resynchronisation Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronisation therapy (CRT) is an established treatment for severe systolic heart
      failure with well documented benefits in symptom improvement and reduction of morbidity and
      mortality. However, upto 30% of patients do not respond to treatment despite fulfilling the
      recommended indications. Lack of clinical response may be the result of imperfect left
      ventricular lead placement in the veins around the heart with conventional techniques.
      Optimum lead placement may constrained by coronary venous anatomy and may overlie scarred
      heart muscle or may not be at the site of latest electrical depolarisation. In a further 10%
      of patients, conventional left ventricular lead placement is not possible for other technical
      reasons.

      Left ventricular endocardial lead placement may overcome the limitations and allow placement
      to be guided by echocardiography, electrical mapping and the pattern of heart muscle
      scarring.

      We aim to investigate if targeted left ventricular endocardial lead placement improves
      exercise capacity, heart failure symptoms, heart function and size, heart pumping efficiency
      and biochemical markers of heart strain. Each parameter will be assessed independently and as
      part of a composite cardiac performance score.

      Patients with heart failure will be enrolled who require an endocardial left ventricular lead
      on clinical grounds as either conventional left ventricular lead implantation has technically
      failed or they have clinically non-responded to CRT.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiopulmonary Exercise Test</measure>
    <time_frame>3 months</time_frame>
    <description>Improvement in peak oxygen consumption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New NYHA Class</measure>
    <time_frame>3 months</time_frame>
    <description>Change in New York Heart Association functional Class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk</measure>
    <time_frame>3 months</time_frame>
    <description>Change in 6 minute hall walk test distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Minnesota Living with heart failure questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>3 months</time_frame>
    <description>Change in size and function of the heart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital photoplethysmography</measure>
    <time_frame>3 months</time_frame>
    <description>Cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical response</measure>
    <time_frame>3 months</time_frame>
    <description>Change in eGFR (estimated glomerular filtration rate) and NT pro BNP (N terminal pro brain natriuretic peptide) levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite cardiac assessment score</measure>
    <time_frame>3 months</time_frame>
    <description>Change in composite assessment score made up of symptom, exercise tolerance, echocardiographic and biochemical parameters.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Freedom from adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Acute: Tamponade, effusion, systemic thromboembolism; acute lead displacement and arrhythmia
Chronic: systemic thromboembolism; lead displacement, disfunction or fracture; device related systemic infection; bleeding; arrhythmia</description>
  </other_outcome>
  <other_outcome>
    <measure>Medium term clinical outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Assess medium term response to treatment with regards to symptoms, exercise tolerance, echocardiographic and biochemical parameters (as specified above), particularly systemic thrombosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Targeting success</measure>
    <time_frame>Intra operative</time_frame>
    <description>Success at targeting the site which produces the greatest haemodynamic response using echocardiogaphic speckle tracking, endocardial electrical mapping and myocardial perfusion scintigraphy.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Active Bi-ventricular Pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No Biventricular pacing</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Targeted left ventricular endocardial lead placement</intervention_name>
    <description>The left ventricular endocardial lead will be passed through the intra-atrial septum</description>
    <arm_group_label>Active Bi-ventricular Pacing</arm_group_label>
    <arm_group_label>No Biventricular pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years

          -  NYHA class II-IV

          -  LVEF ≤35%

          -  QRS ≥120 milliseconds

          -  Optimal tolerated medical therapy

          -  Either unable to position an LV lead via the standard coronary sinus on CRT
             implantation

          -  OR Recipient of a CRT-P or CRT-D system for greater than 6 months for standard
             indications AND limited improvement or worsened clinical status despite device
             optimisation

          -  Informed consent

        Exclusion Criteria:

          -  Life-expectancy less than 1 year due to concomitant, non-cardiovascular disorders

          -  Previous atrial septal defect device closure.

          -  Chronic renal dialysis and End stage liver disease

          -  History of stroke, myocardial infarction, unstable angina, Coronary artery bypass
             grafting and coronary stenting within the last 3 months

          -  Presence of correctable valvular disease (aortic/mitral)

          -  Mitral valve prosthesis.

          -  Contra indication to vitamin K antagonist

          -  Unresolved intra-cardiac thrombus

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Wong, MD FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton and Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Butcher, MBBS MRCP</last_name>
    <email>c.butcher@rbht.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Brompton and Harefield NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Butcher, MBBS MRCP</last_name>
      <email>c.butcher@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tom Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49. Epub 2005 Mar 7.</citation>
    <PMID>15753115</PMID>
  </reference>
  <reference>
    <citation>McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33(14):1787-847. doi: 10.1093/eurheartj/ehs104. Epub 2012 May 19. Erratum in: Eur Heart J. 2013 Jan;34(2):158.</citation>
    <PMID>22611136</PMID>
  </reference>
  <reference>
    <citation>Gras D, Böcker D, Lunati M, Wellens HJ, Calvert M, Freemantle N, Gervais R, Kappenberger L, Tavazzi L, Erdmann E, Cleland JG, Daubert JC; CARE-HF Study Steering Committee and Investigators. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace. 2007 Jul;9(7):516-22. Epub 2007 May 31.</citation>
    <PMID>17540662</PMID>
  </reference>
  <reference>
    <citation>Jaïs P, Douard H, Shah DC, Barold S, Barat JL, Clémenty J. Endocardial biventricular pacing. Pacing Clin Electrophysiol. 1998 Nov;21(11 Pt 1):2128-31.</citation>
    <PMID>9826866</PMID>
  </reference>
  <reference>
    <citation>van Gelder BM, Scheffer MG, Meijer A, Bracke FA. Transseptal endocardial left ventricular pacing: an alternative technique for coronary sinus lead placement in cardiac resynchronization therapy. Heart Rhythm. 2007 Apr;4(4):454-60. Epub 2006 Nov 29.</citation>
    <PMID>17399634</PMID>
  </reference>
  <reference>
    <citation>Nuta B, Lines I, MacIntyre I, Haywood GA. Biventricular ICD implant using endocardial LV lead placement from the left subclavian vein approach and transseptal puncture via the transfemoral route. Europace. 2007 Nov;9(11):1038-40. Epub 2007 Aug 17.</citation>
    <PMID>17704095</PMID>
  </reference>
  <reference>
    <citation>Jaïs P, Takahashi A, Garrigue S, Yamane T, Hocini M, Shah DC, Barold SS, Deisenhofer I, Haïssaguerre M, Clémenty J. Mid-term follow-up of endocardial biventricular pacing. Pacing Clin Electrophysiol. 2000 Nov;23(11 Pt 2):1744-7.</citation>
    <PMID>11139915</PMID>
  </reference>
  <reference>
    <citation>Spragg DD, Dong J, Fetics BJ, Helm R, Marine JE, Cheng A, Henrikson CA, Kass DA, Berger RD. Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2010 Aug 31;56(10):774-81. doi: 10.1016/j.jacc.2010.06.014.</citation>
    <PMID>20797490</PMID>
  </reference>
  <reference>
    <citation>Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O'Halloran D, Elsik M, Read PA, Begley D, Fynn SP, Dutka DP. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol. 2012 Apr 24;59(17):1509-18. doi: 10.1016/j.jacc.2011.12.030. Epub 2012 Mar 7.</citation>
    <PMID>22405632</PMID>
  </reference>
  <reference>
    <citation>Saba S, Marek J, Schwartzman D, Jain S, Adelstein E, White P, Oyenuga OA, Onishi T, Soman P, Gorcsan J 3rd. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region trial. Circ Heart Fail. 2013 May;6(3):427-34. doi: 10.1161/CIRCHEARTFAILURE.112.000078. Epub 2013 Mar 8.</citation>
    <PMID>23476053</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiac Resynchronisation Therapy</keyword>
  <keyword>Transseptal left ventricular endocardial lead</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

